Arthritis & rheumatology (Hoboken, N.J.) · 2026
Where We Live Matters: Varied Disease Burden and Treatment Patterns in Psoriatic Arthritis in the United States.
СтатьяПоддержка NIH: внешняя программаНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Banbury Brittany, Dowell Sharon, Jenkins Christopher, Holladay Emily E, Xie Fenglong, Zhang Jingyi, Wright Grace C, Curtis Jeffrey R, Kerr Gail S
Аннотация
OBJECTIVE: To evaluate the clinical characteristics, social deprivation, insurance coverage, and medication use across regional subsets of patients with psoriatic arthritis (PsA) in the US.
METHODS: A cross-sectional study of patients with PsA in the Rheumatology Informatics System for Effectiveness (RISE) registry between January 2020 and March 2023 was conducted. Distribution of high disease activity (HDA; Routine Assessment of Patient Index Data >12), high comorbidity (RxRisk ≥90th percentile), high Area Deprivation Index (ADI ≥80), insurance coverage, prednisone ≥10 mg daily, and all disease-modifying antirheumatic drug (DMARD) therapies across geographic regions were evaluated. Logistic regression models were used to identify regional correlates of HDA and comorbidity.
RESULTS: Of the 32,732 RISE patients with PsA, 58.8% were White women (mean age 57.7 [SD 13.5] years) with private insurance (60%); 55.8% resided in the South. A majority (81.8%) had a body mass index of ≥25, highest in the Midwest (mean 32.4 ± SD 7.8). Women, despite having prevalent HDA, received less biologic DMARD therapy. Both HDA and ADI of ≥80 were more prevalent in the South and Midwest. Compared to the Northeast, Midwest patients had a higher burden of comorbidity (adjusted odds ratio 1.59, 95% confidence interval 0.98 - 2.59) with frequent use of prednisone in conjunction with conventional DMARDs (31.3% vs Northeast 20.5%, South 13.6%, West 17.6%). Uveitis affected 1.2% of the cohort. Only 14 (7.1%) and 20 (10.1%) RISE practices provided care for half of all Medicaid and high-deprivation patients, respectively.
CONCLUSION: PsA disease characteristics and care vary across the US, with higher-than-expected prednisone use and unequal provider care burden in some regions. Further work is needed to assess the impact of varied regional care on disease outcomes.
METHODS: A cross-sectional study of patients with PsA in the Rheumatology Informatics System for Effectiveness (RISE) registry between January 2020 and March 2023 was conducted. Distribution of high disease activity (HDA; Routine Assessment of Patient Index Data >12), high comorbidity (RxRisk ≥90th percentile), high Area Deprivation Index (ADI ≥80), insurance coverage, prednisone ≥10 mg daily, and all disease-modifying antirheumatic drug (DMARD) therapies across geographic regions were evaluated. Logistic regression models were used to identify regional correlates of HDA and comorbidity.
RESULTS: Of the 32,732 RISE patients with PsA, 58.8% were White women (mean age 57.7 [SD 13.5] years) with private insurance (60%); 55.8% resided in the South. A majority (81.8%) had a body mass index of ≥25, highest in the Midwest (mean 32.4 ± SD 7.8). Women, despite having prevalent HDA, received less biologic DMARD therapy. Both HDA and ADI of ≥80 were more prevalent in the South and Midwest. Compared to the Northeast, Midwest patients had a higher burden of comorbidity (adjusted odds ratio 1.59, 95% confidence interval 0.98 - 2.59) with frequent use of prednisone in conjunction with conventional DMARDs (31.3% vs Northeast 20.5%, South 13.6%, West 17.6%). Uveitis affected 1.2% of the cohort. Only 14 (7.1%) and 20 (10.1%) RISE practices provided care for half of all Medicaid and high-deprivation patients, respectively.
CONCLUSION: PsA disease characteristics and care vary across the US, with higher-than-expected prednisone use and unequal provider care burden in some regions. Further work is needed to assess the impact of varied regional care on disease outcomes.